Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Impact of Pharmacokinetic–Pharmacodynamic Models: Regulatory Decisions

Impact of Pharmacokinetic–Pharmacodynamic Models: Regulatory Decisions

PK–PD modeling has significantly influenced FDA regulatory decisions, particularly drug approval, dosage optimization, and labeling. These models integrate pharmacokinetics (PK) and pharmacodynamics (PD) to predict drug behavior and effects, aiding in optimizing dosing regimens and enhancing the probability of clinical trial success.One notable example is Nesiritide (Natrecor®), a recombinant human brain natriuretic peptide for treating acute decompensated congestive heart failure (CHF).

Pharmaceutical Alternatives: Polymorphic Form-Related and Particle Size-Related Therapeutic Nonequivalence

Pharmaceutical Alternatives: Polymorphic Form-Related and Particle Size-Related Therapeutic Nonequivalence

Changes in polymorphic forms can significantly influence the bioavailability of poorly soluble drugs. Although the FDA defines pharmaceutical equivalence based on having the same active ingredient, dosage form, and route of administration, it does not automatically disqualify products with different polymorphic forms. This means two products with different polymorphs can still be deemed pharmaceutically equivalent. However, polymorphic differences can affect properties like wettability,...

FDA Approved Drugs: Changes to Approved Drugs

FDA Approved Drugs: Changes to Approved Drugs

Post-approval, manufacturers may modify an approved new or generic drug product. Such modifications can encompass alterations in the Active Pharmaceutical Ingredient (API), manufacturing process, formulation, batch size, manufacturing site, and container closure system (FDA Guidance for Industry, April 2004). Often, a drug product may undergo multiple changes.These modifications require careful evaluation to determine their potential impact on the drug product's identity, strength, quality,...

Pharmaceutical Alternatives: Stability-Related Therapeutic Nonequivalence

Pharmaceutical Alternatives: Stability-Related Therapeutic Nonequivalence

Generic intravenous (IV) drugs are considered bioequivalent to their branded counterparts due to their 100% bioavailability upon administration. However, variations in stability among different drug products can significantly influence their therapeutic performance, even if they are pharmaceutically equivalent.Cefuroxime, a prophylactic antimicrobial, is often used as a single-dose IV injection for patients undergoing coronary artery bypass grafting surgery. A 3 g dose typically provides...

Drug Regulation

Drug Regulation

Drug regulation encompasses the management of drug usage by evaluating its safety and efficacy through assessments conducted by regulatory authorities. Regrettably, the history of drug regulation is marred by several catastrophic events. One such incident is the Elixir Sulfanilamide tragedy, in which the toxic compound diethyl glycol was included in a sweet-tasting medication, leading to numerous fatalities. This event prompted the enactment of the Food, Drug, and Cosmetic Act in 1938. Under...

Drug Products: Biologics, Biosimilars and Interchangeables

Drug Products: Biologics, Biosimilars and Interchangeables

Biologics, derived from living sources such as humans, animals, or microorganisms, represent a significant category of pharmaceuticals. These complex molecules, developed through advanced biotechnological methods or purified from natural sources, include essential medical treatments like insulin and growth hormones. The complexity of biologics arises from their large molecular structures and the intricate processes required for their production, making them distinct from conventional...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Black Lives <i>Do</i> Matter.

American journal of pharmaceutical education·2021

Same author

Treatment of Achromobacter Ventilator-Associated Pneumonia in Critically Ill Trauma Patients.

The Annals of pharmacotherapy·2017

Same author

The Use of Topical Hemostatic Agents in Cardiothoracic Surgery.

The Annals of thoracic surgery·2017

Same author

Pharmacokinetics of Imipenem/Cilastatin Burn Intensive Care Unit Patients Undergoing High-Dose Continuous Venovenous Hemofiltration.

Pharmacotherapy·2016

Same author

Short-duration treatment for catheter-associated urinary tract infections in critically ill trauma patients.

The journal of trauma and acute care surgery·2015

Same author

Adjunctive intraventricular antibiotic therapy for bacterial central nervous system infections in critically ill patients with traumatic brain injury.

The Annals of pharmacotherapy·2015

Search research articles

Related Experiment Video

Updated: Jun 12, 2026

Drug Repurposing Hypothesis Generation Using the "RE:fine Drugs" System

Drug Repurposing Hypothesis Generation Using the "RE:fine Drugs" System

Published on: December 11, 2016

Formulary decisions: then and now.

Bradley A Boucher¹

¹Department of Clinical Pharmacy, University of Tennessee Health Science Center, Memphis, Tennessee 38163-0001, USA. bboucher@uthsc.edu

Pharmacotherapy

|May 27, 2010

Summary

Hospital formularies are evolving beyond simple drug lists to complex cost-management tools. Pharmacists must consider safety protocols, risk evaluation and mitigation strategies (REMS), and potential penalties when making formulary decisions.

Area of Science:

Health Administration
Pharmacoeconomics
Drug Management

Background:

Hospital formularies have evolved from basic drug lists to integral components of healthcare administration.
The scope of formulary management has expanded significantly due to increased regulatory scrutiny and safety considerations.

Purpose of the Study:

To highlight the evolving complexities of hospital formulary decision-making.
To emphasize the need for a broader assessment beyond cost-effectiveness and acquisition prices.

Main Methods:

Review of current trends in drug management and institutional policies.
Analysis of factors influencing formulary decisions, including regulatory requirements and safety protocols.

Main Results:

More Related Videos

Improving IV Insulin Administration in a Community Hospital

Improving IV Insulin Administration in a Community Hospital

Published on: June 11, 2012

Related Experiment Videos

Last Updated: Jun 12, 2026

Drug Repurposing Hypothesis Generation Using the "RE:fine Drugs" System

Drug Repurposing Hypothesis Generation Using the "RE:fine Drugs" System

Published on: December 11, 2016

Improving IV Insulin Administration in a Community Hospital

Improving IV Insulin Administration in a Community Hospital

Published on: June 11, 2012

Formulary decisions now encompass a wide range of financial and operational considerations.
Costs associated with black-box warnings, safety protocols, and risk evaluation and mitigation strategies (REMS) significantly impact drug choices.

Conclusions:

Pharmacists face a complex environment requiring comprehensive evaluation of formulary agents.
Future formulary considerations may include "never events" and their financial implications, necessitating strategic planning.